Novo Nordisk lowers full-year profit guidance as sales slow

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk (NVO, NOVO-B.CO) lowered its full-year profit and sales forecast on Wednesday in an early blow to the Danish drugmaker's new CEO while it strives to claw back lost ground in a fierce obesity drug market battle. The Danish drugmaker is going through a tumultuous period marked by a sharp share price plunge and slowing sales growth, which have prompted a change of CEO and a board shake-up. Shares rose over 2% in Copenhagen and in New York before the bell on We ...